X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 51 filers reported holding X4 PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $406,781 | +367.6% | 373,193 | +732.3% | 0.00% | – |
Q2 2023 | $86,985 | +32116.7% | 44,838 | +16384.6% | 0.00% | – |
Q4 2022 | $270 | – | 272 | +27100.0% | 0.00% | – |
Q3 2022 | $0 | – | 1 | 0.0% | 0.00% | – |
Q2 2022 | $0 | -100.0% | 1 | -100.0% | 0.00% | – |
Q1 2022 | $11,000 | -50.0% | 6,245 | -33.6% | 0.00% | – |
Q4 2021 | $22,000 | -75.8% | 9,406 | -45.3% | 0.00% | – |
Q3 2021 | $91,000 | -38.1% | 17,182 | -23.7% | 0.00% | – |
Q2 2021 | $147,000 | -46.2% | 22,518 | -29.0% | 0.00% | – |
Q1 2021 | $273,000 | +116.7% | 31,703 | +61.3% | 0.00% | – |
Q4 2020 | $126,000 | +18.9% | 19,650 | +25.1% | 0.00% | – |
Q3 2020 | $106,000 | -33.8% | 15,709 | -8.5% | 0.00% | – |
Q2 2020 | $160,000 | +162.3% | 17,174 | +178.8% | 0.00% | – |
Q1 2020 | $61,000 | -10.3% | 6,161 | -2.3% | 0.00% | – |
Q4 2019 | $68,000 | -12.8% | 6,306 | +3.3% | 0.00% | – |
Q3 2019 | $78,000 | +32.2% | 6,104 | +56.0% | 0.00% | – |
Q2 2019 | $59,000 | +59.5% | 3,914 | +83.3% | 0.00% | – |
Q1 2019 | $37,000 | – | 2,135 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,682,000 | 3.48% |
Sio Capital Management, LLC | 804,597 | $6,928,000 | 1.41% |
Bain Capital Life Sciences Investors, LLC | 2,119,540 | $18,249,000 | 1.03% |
SV Health Investors, LLC | 311,490 | $2,682,000 | 1.00% |
Monashee Investment Management LLC | 574,712 | $4,948,000 | 0.76% |
Ikarian Capital, LLC | 2,614,988 | $22,515,000 | 0.76% |
Abingworth LLP | 229,885 | $1,956,000 | 0.68% |
New Leaf Venture Partners, L.L.C. | 335,000 | $2,884,000 | 0.67% |
BVF INC/IL | 1,091,579 | $9,398,000 | 0.35% |
Endurant Capital Management LP | 151,996 | $1,309,000 | 0.34% |